ValiRx Plc operates as a biopharmaceutical company. It engages in the development of novel technologies and products in oncology therapeutics and diagnostics. The company products focuses on the epigenomic analysis and treatment of cancer, as well as the technologies can be also applied in other fields, such as neurology and inflammatory diseases. It operates through the Drug Development and Sale of Self-Test Drug Kits segments. ValiRx was founded on June 1, 2006 and is headquartered in London, the United Kingdom.